
|Articles|February 27, 2006
Par launches advanced formulation of Megace ES
Par Pharmaceutical has launched an advanced formulation of megestrol acetate, Megace ES 625 mg/5 ml (megestrol acetate) oral suspension. Megace ES is indicated for the treatment of anorexia, cachexia, or a significant, unexplained weight loss in patients with a diagnosis of AIDS.
Advertisement
Par launches advanced formulation of Megace ES
Par Pharmaceutical has launched an advanced formulation of megestrol acetate, Megace ES 625 mg/5 ml (megestrol acetate) oral suspension. Megace ES is indicated for the treatment of anorexia, cachexia, or a significant, unexplained weight loss in patients with a diagnosis of AIDS.
To see more Hot off the Press news articles, click here
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Long-Term Adverse Effects After COVID-19 Vaccination Vary by Brand
2
Hormone Replacement Therapy May Lower Dementia Risk in Postmenopausal Women
3
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
4
AI, Automation Are Transforming Pharmacies into Proactive Care Hubs
5







































